Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Breast 3Plasma cell 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × copanlisib × Other solid neoplasm × Clear all
NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡